Cargando…

Analytical characterization of coformulated antibodies as combination therapy

When two therapeutic agents are combined in a single formulation, i.e., coformulated, the quality and safety of the individual agents must be preserved. Here we describe an approach to evaluate the quality attributes of two individual monoclonal antibodies (mAbs), designated mAb-A and mAb-B, in cofo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jun, Kim, Yoen Joo, Cao, Mingyan, De Mel, Niluka, Miller, Kenneth, Bee, Jared S., Wang, Jihong, Wang, Xiangyang, Albarghouthi, Methal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153825/ https://www.ncbi.nlm.nih.gov/pubmed/32138591 http://dx.doi.org/10.1080/19420862.2020.1738691

Ejemplares similares

Charge variants characterization and release assay development for co-formulated antibodies as a combination therapy
por: Cao, Mingyan, et al.
Publicado: (2019)

Rapid monitoring of high‐mannose glycans during cell culture process of therapeutic monoclonal antibodies using lectin affinity chromatography
por: Kim, Jun, et al.
Publicado: (2022)

Stability Convergence in Antibody Coformulations
por: Zhang, Hongyu, et al.
Publicado: (2022)

Injectable Coformulations in Diabetology
por: Kalra, Sanjay, et al.
Publicado: (2015)

Impact of Fc N-linked glycans on in vivo clearance of an immunoglobulin G1 antibody produced by NS0 cell line
por: Kim, Jun, et al.
Publicado: (2020)

Erratum to: Injectable Coformulations in Diabetology
por: Kalra, Sanjay, et al.
Publicado: (2015)

Coformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studies
por: Patel, Ashaben, et al.
Publicado: (2018)

Stability enhancement in a mAb and Fab coformulation
por: Zhang, Hongyu, et al.
Publicado: (2020)

Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis
por: Cao, Mingyan, et al.
Publicado: (2019)

A systematic approach for analysis and characterization of mispairing in bispecific antibodies with asymmetric architecture
por: Wang, Chunlei, et al.
Publicado: (2018)

Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide
por: Custodio, Joseph M., et al.
Publicado: (2017)

Characterization of IgG1 Fc Deamidation at Asparagine 325 and Its Impact on Antibody-dependent Cell-mediated Cytotoxicity and FcγRIIIa Binding
por: Lu, Xiaojun, et al.
Publicado: (2020)

Characterization and analysis of scFv-IgG bispecific antibody size variants
por: Cao, Mingyan, et al.
Publicado: (2018)

Quantitative Proteomics Reveals Transforming Growth Factor β Receptor Targeted by Resveratrol and Hesperetin Coformulation in Endothelial Cells
por: Mestareehi, Aktham, et al.
Publicado: (2023)

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018)

Meta-Analysis of Efficacy and Safety of Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV
por: Chen, I-Wen, et al.
Publicado: (2021)

Unveiling Coformulants in Plant Protection Products by LC-HRMS Using a Polyhydroxy Methacrylate Stationary Phase
por: Martín-García, Beatriz, et al.
Publicado: (2023)

Multiplex Bioanalytical Methods for Comprehensive Characterization and Quantification of the Unique Complementarity-Determining-Region Deamidation of MEDI7247, an Anti-ASCT2 Pyrrolobenzodiazepine Antibody–Drug Conjugate
por: Huang, Yue, et al.
Publicado: (2023)

Coformulation of a Novel Human α-Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry Mice
por: Xu, Su, et al.
Publicado: (2015)

Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?
por: Nachega, Jean B, et al.
Publicado: (2011)

First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics
por: Friedland, Barbara A., et al.
Publicado: (2016)

Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
por: Liou, Bo-Huang, et al.
Publicado: (2021)

Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults
por: Singh, Rajendra P., et al.
Publicado: (2018)

Atypical Asparagine Deamidation of NW Motif Significantly Attenuates the Biological Activities of an Antibody Drug Conjugate
por: Cao, Mingyan, et al.
Publicado: (2023)

An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1
por: Liu, An, et al.
Publicado: (2022)

Short‐course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide
por: Liou, Bo‐Huang, et al.
Publicado: (2021)

A Quadrupole Dalton-based multi-attribute method for product characterization, process development, and quality control of therapeutic proteins
por: Xu, Weichen, et al.
Publicado: (2017)

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera(®)). Efficacy and safety analysis. GeSida Study 8114
por: Pérez-Hernández, Isabel A, et al.
Publicado: (2014)

Phytochemical Curcumin-Coformulated, Silver-Decorated Melanin-like Polydopamine/Mesoporous Silica Composites with Improved Antibacterial and Chemotherapeutic Effects against Drug-Resistant Cancer Cells
por: Song, Yiyan, et al.
Publicado: (2020)

Uncovering the Dissipation of Chlorantraniliprole in Tomatoes: Identifying Transformation Products (TPs) and Coformulants in Greenhouse and Laboratory Studies by UHPLC-Q-Orbitrap-MS and GC-Q-Orbitrap-MS
por: Maldonado-Reina, Antonio Jesús, et al.
Publicado: (2023)

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
por: Pozniak, Anton, et al.
Publicado: (2016)

Analytical Techniques for the Characterization and Quantification of Monoclonal Antibodies
por: Alhazmi, Hassan A., et al.
Publicado: (2023)

Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients
por: Huang, Yu-Shan, et al.
Publicado: (2023)

Effects of antibody disulfide bond reduction on purification process performance and final drug substance stability
por: Chung, Wai Keen, et al.
Publicado: (2017)

Antibodies and antibody-derived analytical biosensors
por: Sharma, Shikha, et al.
Publicado: (2016)

Analytic real algebras
por: Seo, Young Joo, et al.
Publicado: (2016)

Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1
por: Chen, Weimin, et al.
Publicado: (2021)

Process Analytical Technologies and Data Analytics for the Manufacture of Monoclonal Antibodies
por: Maruthamuthu, Murali K., et al.
Publicado: (2020)

Effect of Strychinine, a Glycine Inhibitor, on the Programmed Cell Death of Motoneurons during the Chick Development
por: Kim, Joo Yeon, et al.
Publicado: (2011)

Assessing analytical methods to monitor isoAsp formation in monoclonal antibodies
por: Eakin, Catherine M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dooj3ncr660edjp192se63i1ut